Coultreon Biopharma BV

Onco3R Therapeutics unveiled a new name and a fresh financing on Tuesday. Now operating as Coultreon Biopharma, the biotech bagged a $125-million A round backed by big pharma to begin Phase II studies of its lead candidate, COL-5671 (formerly O3R-5671). The company is developing therapeutics that modulate salt-inducible kinases (SIKs), a protein family linked to inflammatory pathway regulation, to treat autoimmune diseases. COL-5671 is an oral, once-daily inhibitor of SIK3, a target that Coultreon has identified as a key driver of pathogenic immune signalling. The candidate, currently in Phase I testing, is designed to provide broad and durable disease control by reducing transcription of pro-inflammatory cytokines, including TNFα and IL-23, while boosting expression of the immunoregulatory cytokine IL-10. Sofinnova Investments led the financing, alongside Forbion and Novo Holdings as co-leads. "We have strong conviction in the company's lead SIK3 programme to be valuable across a range of autoimmune diseases where patients would benefit from an alternative oral treatment option," said Maha Katabi, a general partner at Sofinnova. According to Coultreon, COL-5671 has shown sustained suppression of inflammatory cytokines in preclinical and early clinical studies, alongside a tolerable safety profile. The biotech said it plans to use the megaround's funds to launch Phase II studies in psoriasis and ulcerative colitis, while noting that early data also support advancing the asset in Crohn's disease, psoriatic arthritis and rheumatoid arthritis. Clinical proof-of-concept data could be available as early as 2027. Galapagos — which originally developed COL-5671 before transferring the asset to Coultreon last year — also participated in the round, as did Regeneron Ventures, Balyasny Asset Management, Luma Group, Samsara BioCapital, Longwood Fund and Finchley Healthcare Ventures. The content above comes from the network. if any infringement, please contact us to modify.

Leuven-based Coultreon Biopharma, formerly known as Onco3R Therapeutics, has closed a USD 125 million Series A financing round to advance its immunology pipeline, anchored by the oral SIK3 inhibitor COL-5671. Sofinnova Investments led the round, with Forbion and Novo Holdings serving as co-leads. Additional participants included Galapagos, Regeneron Ventures, Balyasny Asset Management, Luma Group, Samsara BioCapital, Longwood Fund, and Finchley Healthcare Ventures. The company said proceeds will support clinical advancement of COL-5671, with Phase II trials in psoriasis and ulcerative colitis planned, and a clinical proof-of-concept readout targeted for 2027. No previous financing rounds were disclosed beyond a seed investment from Galapagos in April 2025, which coincided with the transfer of full ownership of COL-5671 from Galapagos to Coultreon. COL-5671, formerly designated O3R-5671 during its time at Galapagos, is a highly selective, oral once-daily inhibitor of salt-inducible kinase 3 (SIK3). Coultreon’s scientific rationale centers on more than 15 years of research into the SIK family of proteins, which regulate key inflammatory pathways. The company has identified SIK3 as a driver of pathogenic immune signaling, and COL-5671 is designed to reduce transcription of pro-inflammatory cytokines including TNFα and IL-23 while increasing expression of the immunoregulatory cytokine IL-10. The company said early clinical and preclinical data have demonstrated favorable pharmacokinetics with once-daily dosing, sustained cytokine suppression, and a toxicology-supported safety profile. Target indications include ulcerative colitis, Crohn’s disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis. COL-5671 is currently in Phase I studies. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Coultreon launched in June 2025 under the name Onco3R Therapeutics with a clutch of discarded Galapagos assets in hand.\n After launching in 2025 as a refuge for shipwrecked assets from Galapagos, Onco3R Therapeutics is rebranding as Coultreon Biopharma and filling its treasure chest with a $125 million series A.The support comes from Sofinnova Investments, which led the round alongside Forbion and Novo Holdings, the biotech announced in an April 28 release. Galapagos pitched in too, as did Regeneron Ventures, Balyasny Asset Management, Luma Group, Samsara BioCapital, Longwood Fund and Finchley Healthcare Ventures. Coultreon’s pipeline of Galapagos castaways is led by COL-5671, an oral inhibitor of salt-inducible kinase 3 (SIK3), which the Belgian biotech is developing for autoimmune disease. The series A haul will help advance COL-5671 from phase 1 testing to phase 2 studies in psoriasis and ulcerative colitis, according to the release, with Coultreon eyeing a proof-of-concept data readout next year.The rest of Coultreon’s pipeline, according to its website, includes candidates for bladder cancer, lung cancer and solid tumors.“This financing marks a major inflection point for our company,” Pierre Raboisson, Coultreon’s CEO, said in the release. “With the support of this top-tier syndicate, we are well-positioned to advance our SIK program, while unlocking the broader potential of our pipeline.”Raboisson previously served as head of discovery and preclinical development for Galapagos, before departing in June 2025 to get Coultreon (then called Onco3R) off the ground. “We are impressed by Coultreon’s scientific depth, disciplined development strategy, and the strength of its team,” Maha Katabi, general partner at Sofinnova, said in the release. “We have strong conviction in the company’s lead SIK3 program to be valuable across a range of autoimmune diseases where patients would benefit from an alternative oral treatment option.” Coultreon’s founding came at a time of great turbulence for Galapagos. The biotech had announced—and then walked back—plans to split the company and also decided to completely scrap its cell therapy work. Galapagos is now planning to rebrand as Lakefront Biotherapeutics and has been given new life as the lead developer of an autoimmune T-cell engager from Ouro Medicines. Gilead Sciences, which owns 25% of Galapagos, recently acquired Ouro for $2.2 billion.SIK3 and other enzymes in its family are known drivers of inflammation and cancer, but there are currently no approved medicines that target them. German biotech iOmx Therapeutics also has a SIK inhibitor in development for solid tumors, while Pfizer recently dropped a phase 1 colitis candidate of its own from its pipeline.A number of biotechs also have preclinical SIK inhibitors in the works, such as Nimbus Therapeutics and Boehringer Ingelheim-partnered British outfit Sitryx.